EUVIMEDEUVIMED entdecken
Crossref

Legislative and Regulatory Systems for the Blood Supply. Is there any Progress?

Cees Th. Smit Sibinga

Hematology and Disorders · 2024

DOI: 10.58489/2836-3582/014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology and Disorders, 2024. Verfasst von Cees Th. Smit Sibinga.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2021, four years ago, an editorial was published 3 years after the WHO 2019 initiative to include blood, blood components, plasma and plasma derived medicinal products (PDMP) in the WHO Global Benchmarking Tool called GBT+Blood. The burning question raised was: ‘How about the effectiveness’. GBT+Blood was published and distributed some 6 years after the inclusion of labile blood products as special ‘medicines’ in the WHO List of Essential Medicines (2013), accommodated in 2017 by Guidelines on Management of Blood and Blood Components as Essential Medicines, to ease implementation focused on Low- and Middle-Income Countries (World Bank LMICs) or the Low- and Medium- Human Development Index countries (UNDP L- and M-HDI countries). This article raises the question: ‘Is there any progress?’ and attempts to provide a realistic answer based on available literature.

Zitieren

APA

Sibinga, C. T. S. (2024). Legislative and Regulatory Systems for the Blood Supply. Is there any Progress?. Hematology and Disorders. https://doi.org/10.58489/2836-3582/014

Vancouver

Sibinga CTS. Legislative and Regulatory Systems for the Blood Supply. Is there any Progress?. Hematology and Disorders. 2024. doi:10.58489/2836-3582/014

BibTeX
@article{Sibinga2024,
  author = {Sibinga, Cees Th. Smit},
  title = {Legislative and Regulatory Systems for the Blood Supply. Is there any Progress?},
  journal = {Hematology and Disorders},
  year = {2024},
  doi = {10.58489/2836-3582/014}
}
Kostenlos starten →